Developer docs
API playgroundTry for free, no card

Search company profiles

Biocrucible

Full company profile

uuid000afer

Namestring
Biocrucible
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Biocrucible is a privately-held diagnostics company developing next-generation diagnostic products grounded in advances in biomolecular condensate formation. The company's stated proposition centers on leveraging condensate-based chemistry as a differentiated platform for diagnostic applications, a deep-tech approach that contrasts with conventional antibody- or nucleic-acid-based assay architectures. Founded in 2018, the company operates with a headcount in the 11–50 range, consistent with an early-to-mid stage research and development organization that has not yet reached scale commercialization.

The company is headquartered in Cambridge, listed in the input as United States (noting that its registered web domain is biocrucible.co.uk, which is consistent with a UK corporate presence and may indicate a transatlantic structure or a data-entry discrepancy). Leadership comprises David Brooks as Chief Executive Officer and Niall Armes as Chief Scientific Officer, suggesting a lean founder-led operating model in which scientific direction and executive oversight sit with two named individuals. No products, customers, partnerships, funding rounds, regulatory milestones, or revenue figures specific to Biocrucible are disclosed in the available source material; the bulk of the operational data aggregated alongside Biocrucible's firmographics pertains to Sapphiros (a separate diagnostics platform company with Roche, BARDA, NIH, Gates Foundation, and KKR relationships and a 5-billion-unit manufacturing footprint) and is therefore not attributable to Biocrucible for analytical purposes. As a result, the business model, go-to-market motion, customer segmentation, and unit economics for Biocrucible cannot be characterized from the present evidence base and represent a material information gap for any prospective investor or acquirer.

Short descriptiontext

Biocrucible is a privately-held, Cambridge-based diagnostics company founded in 2018 that is developing next-generation diagnostic tests based on proprietary advances in biomolecular condensate formation. It operates with 11–50 employees and is led by CEO David Brooks and CSO Niall Armes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomolecular condensate diagnostics, molecular diagnostic assays, diagnostic platform development, protein condensate detection, clinical biomarker discovery
Industry2 codes
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Products
TypeHardware Sales
Description

Sale of molecular, lateral flow, and digital diagnostic test products across multiple platforms. Large-scale supply agreements with major healthcare partners.

sapphiros.com
2Manufacturing Services
TypeOne Time License
Description

Extreme volume manufacturing capabilities providing capacity for pandemic preparedness and emergency response testing.

sapphiros.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company is leveraging novel biomolecular condensate science to create advanced molecular diagnostic capabilities, building a proprietary technology platform aimed at clinical and research diagnostic applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 5 billion unit annual manufacturing capacity
+1 more record
Product overview1 text field

Sapphiros offers a multi-platform diagnostic product portfolio comprising four core product categories: Handheld 1-step Molecular, Digital Lateral Flow, Blood Collection & Detection, and Lateral Flow tests. These are supported by four key manufacturing and technology capabilities: Extreme Volume Manufacturing (with 5 billion unit capacity), Visual Lateral Flow, Printed Electronics, and In-house molecular reagents. The company focuses on delivering low-cost, easy-to-use, scalable diagnostics for consumer health applications with laboratory-quality accuracy.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

BARDA announced collaboration with Sapphiros for development of an OTC, single-use, low-cost digital antigen test that can detect and differentiate between respiratory viruses. This government partnership supports public health emergency preparedness.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Strategic agreement providing Roche access to 1 billion lateral flow tests annually and access to future molecular point-of-care tests. Agreement secures rapid, global access to tests for future pandemics and health emergencies. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros' 5 billion unit capacity proprietary manufacturing process.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as trusted partner supporting global health initiatives and access to diagnostics for underserved populations worldwide.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as trusted government partner for diagnostic development and healthcare research initiatives.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as trusted partner in the diagnostics ecosystem, providing complementary capabilities in testing technologies.

Peers8 records
TypeDirect peer
Description

Protein biomarker measurement company using aptamer-based binding assays for high-throughput proteomics. Comparable in translating a novel molecular-recognition approach into a commercial proteomics platform.

TypeDirect peer
Description

Provider of high-multiplex protein biomarker analytics (Proximity Extension Assay) for pharma services and diagnostics. Relevant peer because it monetized a novel protein-detection biophysics via kit sales and partnerships.

TypeDirect peer
Description

Developer of ultra-sensitive protein biomarker detection platforms (Simoa) for research and diagnostics. Comparable because both operate in next-generation protein-based diagnostic detection where novel biophysics could translate to differentiated performance.

TypeEmerging player
Description

Single-cell and spatial molecular biology tools that bridge research and clinical diagnostics. Comparable as a life science tools company commercializing a novel platform technology into diagnostics-adjacent markets.

TypeBroad incumbent
Description

Large life science tools and diagnostics supplier with proteomics, immunoassay, and diagnostic reagent product lines. Relevant as a potential strategic acquirer / channel partner for novel protein-based diagnostic platforms.

TypeBroad incumbent
Description

Life science tools company with protein and genomic analysis platforms for research and clinical markets. Comparable as a multi-modality tools/diagnostics vendor where novel assay platforms could be integrated or acquired.

TypeEmerging player
Description

Single-molecule protein analysis platform aiming to characterize the proteome comprehensively. Comparable as an early-stage platform company pursuing a fundamentally different biophysical modality for protein characterization.

TypeBroad incumbent
Description

Multi-platform diagnostics company (molecular, lateral flow, digital) with large-scale manufacturing and global healthcare partnerships. Closely associated with Biocrucible in the source data and represents the broader consumer/professional diagnostics space Biocrucible's platform could plug into.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocrucible

Molecular Diagnosticsbiocrucible.co.uk

Biocrucible is a privately-held, Cambridge-based diagnostics company founded in 2018 that is developing next-generation diagnostic tests based on proprietary advances in biomolecular condensate formation. It operates with 11–50 employees and is led by CEO David Brooks and CSO Niall Armes.

What Biocrucible does

Biocrucible is a privately-held diagnostics company developing next-generation diagnostic products grounded in advances in biomolecular condensate formation. The company's stated proposition centers on leveraging condensate-based chemistry as a differentiated platform for diagnostic applications, a deep-tech approach that contrasts with conventional antibody- or nucleic-acid-based assay architectures. Founded in 2018, the company operates with a headcount in the 11–50 range, consistent with an early-to-mid stage research and development organization that has not yet reached scale commercialization.

The company is headquartered in Cambridge, listed in the input as United States (noting that its registered web domain is biocrucible.co.uk, which is consistent with a UK corporate presence and may indicate a transatlantic structure or a data-entry discrepancy). Leadership comprises David Brooks as Chief Executive Officer and Niall Armes as Chief Scientific Officer, suggesting a lean founder-led operating model in which scientific direction and executive oversight sit with two named individuals. No products, customers, partnerships, funding rounds, regulatory milestones, or revenue figures specific to Biocrucible are disclosed in the available source material; the bulk of the operational data aggregated alongside Biocrucible's firmographics pertains to Sapphiros (a separate diagnostics platform company with Roche, BARDA, NIH, Gates Foundation, and KKR relationships and a 5-billion-unit manufacturing footprint) and is therefore not attributable to Biocrucible for analytical purposes. As a result, the business model, go-to-market motion, customer segmentation, and unit economics for Biocrucible cannot be characterized from the present evidence base and represent a material information gap for any prospective investor or acquirer.

Biocrucible firmographics

Firmographics
Name
Biocrucible
Website
https://biocrucible.co.uk
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Biocrucible is a privately-held, Cambridge-based diagnostics company founded in 2018 that is developing next-generation diagnostic tests based on proprietary advances in biomolecular condensate formation. It operates with 11–50 employees and is led by CEO David Brooks and CSO Niall Armes.
Ownership category
akta.pro rank

Biocrucible industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Biomolecular condensate diagnostics
  • Molecular diagnostic assays
  • Diagnostic platform development
  • Protein condensate detection
  • Clinical biomarker discovery

Where Biocrucible is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Biocrucible business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Diagnostic Test Products: Sale of molecular, lateral flow, and digital diagnostic test products across multiple platforms. Large-scale supply agreements with major healthcare partners.
  2. Manufacturing Services: Extreme volume manufacturing capabilities providing capacity for pandemic preparedness and emergency response testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Biocrucible product offering

Product offering

Core offering

Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company is leveraging novel biomolecular condensate science to create advanced molecular diagnostic capabilities, building a proprietary technology platform aimed at clinical and research diagnostic applications.

Product overview

Sapphiros offers a multi-platform diagnostic product portfolio comprising four core product categories: Handheld 1-step Molecular, Digital Lateral Flow, Blood Collection & Detection, and Lateral Flow tests. These are supported by four key manufacturing and technology capabilities: Extreme Volume Manufacturing (with 5 billion unit capacity), Visual Lateral Flow, Printed Electronics, and In-house molecular reagents. The company focuses on delivering low-cost, easy-to-use, scalable diagnostics for consumer health applications with laboratory-quality accuracy.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 5 billion unit annual manufacturing capacity
  • +1 more outcomes

Companies that use Biocrucible

Customer profile

Named customers4 records

Segments3 records

Biocrucible technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Biocrucible partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and flagship.

  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 December 2025BARDA announced collaboration with Sapphiros for development of an OTC, single-use, low-cost digital antigen test that can detect and differentiate between respiratory viruses. This government partnership supports public health emergency preparedness.
  • RocheflagshipStrategic or Co-development Partner · 19 November 2025Strategic agreement providing Roche access to 1 billion lateral flow tests annually and access to future molecular point-of-care tests. Agreement secures rapid, global access to tests for future pandemics and health emergencies. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros' 5 billion unit capacity proprietary manufacturing process.
  • Gates FoundationcoreStrategic or Co-development PartnerListed as trusted partner supporting global health initiatives and access to diagnostics for underserved populations worldwide.
  • National Institutes of Health (NIH)coreStrategic or Co-development PartnerListed as trusted government partner for diagnostic development and healthcare research initiatives.
  • OraSure TechnologiescoreStrategic or Co-development PartnerListed as trusted partner in the diagnostics ecosystem, providing complementary capabilities in testing technologies.

Scale indicators3 records

Biocrucible competitors and assessment

Company assessment

Direct peers

  • SomaLogic: Protein biomarker measurement company using aptamer-based binding assays for high-throughput proteomics. Comparable in translating a novel molecular-recognition approach into a commercial proteomics platform.
  • Olink: Provider of high-multiplex protein biomarker analytics (Proximity Extension Assay) for pharma services and diagnostics. Relevant peer because it monetized a novel protein-detection biophysics via kit sales and partnerships.
  • Quanterix: Developer of ultra-sensitive protein biomarker detection platforms (Simoa) for research and diagnostics. Comparable because both operate in next-generation protein-based diagnostic detection where novel biophysics could translate to differentiated performance.

Emerging players

  • 10x Genomics: Single-cell and spatial molecular biology tools that bridge research and clinical diagnostics. Comparable as a life science tools company commercializing a novel platform technology into diagnostics-adjacent markets.
  • Nautilus Biotechnology: Single-molecule protein analysis platform aiming to characterize the proteome comprehensively. Comparable as an early-stage platform company pursuing a fundamentally different biophysical modality for protein characterization.

Broad incumbents

  • Bio-Techne: Large life science tools and diagnostics supplier with proteomics, immunoassay, and diagnostic reagent product lines. Relevant as a potential strategic acquirer / channel partner for novel protein-based diagnostic platforms.
  • Standard BioTools: Life science tools company with protein and genomic analysis platforms for research and clinical markets. Comparable as a multi-modality tools/diagnostics vendor where novel assay platforms could be integrated or acquired.
  • Sapphiros: Multi-platform diagnostics company (molecular, lateral flow, digital) with large-scale manufacturing and global healthcare partnerships. Closely associated with Biocrucible in the source data and represents the broader consumer/professional diagnostics space Biocrucible's platform could plug into.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Biocrucible financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocrucible leadership team

Management profile

Number of profiles

Profiles2 records

Biocrucible funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocrucible M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocrucible

What does Biocrucible do?

Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company is leveraging novel biomolecular condensate science to create advanced molecular diagnostic capabilities, building a proprietary technology platform aimed at clinical and research diagnostic applications.

When was Biocrucible founded?

Biocrucible was founded in 2018. It employs 11 to 50 people.

Where is Biocrucible based?

Biocrucible is headquartered in Cambridge, United States, in the North America region.

How does Biocrucible make money?

Two revenue lines are on record. Diagnostic Test Products are the primary driver. The others are manufacturing Services.

Who are Biocrucible's main competitors?

Direct peers on record are SomaLogic, Olink and Quanterix. Emerging players are 10x Genomics and Nautilus Biotechnology. Broad incumbents are Bio-Techne, Standard BioTools and Sapphiros.

Does Biocrucible have an API?

No public API is recorded for Biocrucible.

What industry is Biocrucible in?

Biocrucible's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals